Oric Pharmaceuticals, Inc. ORIC Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Oric Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oric Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oric Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Oric Pharmaceuticals, Inc. (ORIC) reported accretion (amortization) of discounts and premiums, investments of -$162K in Q1 2026.
- How has Oric Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Oric Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 118.4% year-over-year, from $882K to -$162K.
- What is the long-term trend for Oric Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 14.3% compound annual growth rate (CAGR), from -$1.35M to $2.3M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric represents the non-cash adjustments to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts. It reflects the gradual adjustment of investment yields toward the market rate over the life of the security. Investors use this to reconcile reported net income with actual cash flows generated from investment portfolios.